NEW DATA SHOW ORAL FERRIC MALTOL (FERACCRU®) MAY BE A COST-EFFECTIVE ALTERNATIVE TO INTRAVENOUS (IV) CARBOXYMALTOSE WITH AT LEAST AS GREAT BENEFITS IN THE QUALITY OF LIFE OF PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INFLAMMATORY BOWEL DISEASE (IBD)
19 February 2020
NORGINE B.V. ENTERS INTO EXCLUSIVE LICENCE AND DISTRIBUTION AGREEMENTS FOR THE COMMERCIALISATION OF PLENVU® IN A NUMBER OF COUNTRIES IN LATIN AMERICA, SOUTHERN AFRICA, CENTRAL AND EASTERN EUROPE
12 February 2020
We believe in interacting with and providing support to patient organisations to ensure high quality provision of information for patients so that, in consultation with their healthcare professionals, they can make well-informed choices about their health and treatment and ultimately improve their experience and outcomes.
In keeping with our long term strategy, our focus continues to be on the devolving and commercialising specialist products that address significant unmet clinical need in gastroenterology, hepatology, cancer and supportive care.
We provide support to patient groups through grants and sponsorship.
As a leader in bowel cleansing and colonoscopy, we are collaborating with key patient organisations both pan-European and country-specific to increase the detection of colorectal cancer and to help improve patients’ quality of life and save lives.
Colorectal cancer is the second most common cause of cancer-related mortality in the world,1 with nearly 1.4 million new cases diagnosed worldwide and 412,000 people in Europe.2,3
Unfortunately, poor diets and sedentary lifestyles are contributing to a resurgence of this deadly disease – young adults are now 4 times more likely to develop the disease than in 1970s.4
1 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403
2 Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-
figures/ data-specific- cancers/colorectal-cancer- statistics [Accessed 3 March 2016].
3 Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915.
4 R. Siegel et al.Colorectal Cancer Incidence Patterns in the United States, 1974–2013. J Natl Cancer Inst (2017)
109 (8): djw322.
We are collaborating with patient groups both pan-European and country-specific to ensure better outcomes for patients and appropriate utilisation of healthcare resources. It is important that hepatic encephalopathy is recognised as a life threatening condition and healthcare systems report it like other critical conditions, so that patients can be managed accordingly.
Hepatic encephalopathy is a serious and potentially life-threatening neuropsychiatric condition associated with liver cirrhosis1. In Europe 200,0002 people are affected by hepatic encephalopathy yet it remains under-diagnosed and under-treated, as many patients and carers are unaware of the signs and symptoms of the disease. This results in poor quality of life for patients and a high burden on those who care for them.3,4 Healthcare providers don’t always identify and treat the often subtle symptoms of hepatic encephalopathy which leads to mediocre patient outcomes and an increase in hospital admissions.5
In collaboration with the European Liver Patients Association (ELPA) we launched a report Time to DeLiver: Getting a Grip on hepatic encephalopathy which aims to drive change in the perception, identification and management of hepatic encephalopathy and to date remains the only report in Europe for this disease.
1 Patidar KR. et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014. 109. 1757-63.
2 Amodio P, Del Piccolo F, Pettenò E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001;35(1):37-45.
3 Jasmohan S. Bajaj. et al. The Multi-Dimensional Burden of Cirrhosis and Hepatic
Encephalopathy on Patients and Caregivers. Am J Gastroenterol. 2011 Sep; 106(9): 1646–1653.
4 A. Sanyal. et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy – a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011 Oct;34(8):853-61.
5 Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology 2014; 61(3):642-659
We are working with patient groups, both pan-European and country-specific to improve understanding of this disease and the importance of early diagnosis.
There are an estimated 400,000 to 600,000 new cases of all types of head and neck cancer globally each year and the mortality rate is between 223,000 and 300,000 deaths per year.1 Head and neck cancer is the seventh most common type of cancer in Europe, with more than 150,000 new patients diagnosed in Europe in 2012.2
We partner with the Make Sense campaign, which is led by the European Head and Neck Society (EHNS). The collaboration aims to raise awareness of sentinel lymph node biopsy, mapping and identification in head and neck cancer treatment. It also aims to highlight the importance of nuclear medicine as a critical part of the multi-disciplinary team.
1 http://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf accessed on 14th March 2017
2 http://makesensecampaign.eu/en/cancer-information/head-neck-cancer/ accessed on 14th March 2017